EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Enzalutamide Versus Abiraterone After Docetaxel in Metastatic Castration-Resistant Prostate Cancer: Real-World Outcomes and Exploratory Prognostic Stratification

Mert Tohumcuoğlu iD, Tolga Köşeci, Alpay Düşgün iD, Abdullah Evren Yetişir, Cem Mirili iD, Burak Mete iD, Mahmut Büyükşimşek iD

Journal of Clinical Medicine · 21.06.2026 · 15 (12) · 4816

DOI: 10.3390/jcm15124816 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Medicine, online erschienen am 21.06.2026. Verfasst von Mert Tohumcuoğlu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Adana City Training and Research Hospital, University of Health Sciences, Adana 01230, Türkiye. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Objectives: Enzalutamide and abiraterone acetate are commonly used androgen receptor pathway inhibitors in metastatic castration-resistant prostate cancer (mCRPC), including after docetaxel. However, real-world outcomes remain heterogeneous, and simple prognostic markers may help describe this variability. This study aimed to describe survival outcomes with enzalutamide and abiraterone acetate after docetaxel and to explore the prognostic value of a routine clinical-inflammatory risk classification.

Methods

This retrospective single-center study included 136 patients with mCRPC treated with enzalutamide or abiraterone acetate after docetaxel. A composite risk classification was defined using four routinely available variables: pan-immune-inflammation value (PIV) > 457.99, time to castration resistance < 12 months, baseline hemoglobin ≤ 12 g/dL, and Gleason score ≥ 8. One point was assigned for each adverse factor, and patients were classified as low, moderate, or high risk. Overall survival (OS) was assessed using Kaplan–Meier estimates and Cox regression. The prognostic score and Cox regression-based nomogram were evaluated as exploratory tools.

Results

Of the 136 patients, 8 (5.9%) were classified as low risk, 67 (49.3%) as moderate risk, and 61 (44.9%) as high risk. Median OS was not reached in the low-risk group, compared with 33.84 months in the moderate-risk group and 9.66 months in the high-risk group. In multivariable analysis, high-risk status was independently associated with worse OS (HR = 9.87; 95% CI: 2.38–40.92; p = 0.002). No statistically significant OS difference was observed between enzalutamide and abiraterone acetate in this non-randomized cohort (HR = 1.36; 95% CI: 0.90–2.06; p = 0.142).

Conclusions

In this real-world post-docetaxel mCRPC cohort, no statistically significant OS difference was observed between enzalutamide and abiraterone acetate; however, the study was not designed to establish comparative effectiveness or therapeutic equivalence. The exploratory risk classification based on routine clinical and inflammatory variables was associated with distinct survival outcomes. External validation is required before clinical application.

Schlagwörter

Stichwörter der Autor:innen

abiraterone acetatedocetaxelenzalutamidemetastatic castration-resistant prostate cancernomogramoverall survivalpan-immune-inflammation valueprognostic score

Autor:innen und Institutionen

  • Department of Medical Oncology, Adana City Training and Research Hospital, University of Health Sciences, Adana 01230, Türkiye.
  • Department of Medical Oncology, Faculty of Medicine, Çukurova University, Adana 01330, Türkiye.
  • Medical Oncology Clinic, Adana Ortadoğu Hospital, Adana 01140, Türkiye.
  • Department of Public Health, Faculty of Medicine, Çukurova University, Adana 01330, Türkiye.

ORCID-Profile: Mert Tohumcuoğlu, Alpay Düşgün, Cem Mirili, Burak Mete, Mahmut Büyükşimşek

Zitieren

APA

Tohumcuoğlu, M., Köşeci, T., Düşgün, A., Yetişir, A. E., Mirili, C., Mete, B., & Büyükşimşek, M. (2026). Enzalutamide Versus Abiraterone After Docetaxel in Metastatic Castration-Resistant Prostate Cancer: Real-World Outcomes and Exploratory Prognostic Stratification. Journal of Clinical Medicine, 15(12), 4816. https://doi.org/10.3390/jcm15124816

Vancouver

Tohumcuoğlu M, Köşeci T, Düşgün A, Yetişir AE, Mirili C, Mete B, et al. Enzalutamide Versus Abiraterone After Docetaxel in Metastatic Castration-Resistant Prostate Cancer: Real-World Outcomes and Exploratory Prognostic Stratification. Journal of Clinical Medicine. 2026;15(12):4816. doi:10.3390/jcm15124816

BibTeX
@article{Tohumcuolu2026,
  author = {Tohumcuoğlu, Mert and Köşeci, Tolga and Düşgün, Alpay and Yetişir, Abdullah Evren and Mirili, Cem and Mete, Burak and Büyükşimşek, Mahmut},
  title = {Enzalutamide Versus Abiraterone After Docetaxel in Metastatic Castration-Resistant Prostate Cancer: Real-World Outcomes and Exploratory Prognostic Stratification},
  journal = {Journal of Clinical Medicine},
  year = {2026},
  volume = {15},
  number = {12},
  pages = {4816},
  doi = {10.3390/jcm15124816}
}
Kostenlos starten →